Avastin (bevacizumab) is approved to treat metastatic colorectal cancer, or mCRC, for first- or second-line treatment in combination with intravenous fluorouracil–based chemotherapy. Avastin is also approved as a second-line treatment, when used with fluoropyrimidine-based (combined with irinotecan or oxaliplatin) chemotherapy, after cancer progresses following a first-line treatment that includes Avastin.
Keep in mind that Avastin is not approved for use after surgery was used as the primary treatment in patients with colon cancer which has not spread to other parts of the body.
Patients with recurrent glioblastoma (a form of brain cancer) who were treated with Avastin® (bevacizumab) alone experienced a slight survival advantage compared with patients treated with Avastin plus Camptosar® (irinotecan). These results were presented at the 2008 annual meeting of the American Society of Clinical Oncology.